Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35+
SponsorDanish Research Centre for Magnetic Resonance

About this trial

The goal of this observational study is to investigate whether the healthy human brain shows a diversity of optimistic and pessimistic reward signals and whether changes in this distribution in Parkinson's disease (PD) can provide mechanistic insights into the cause of symptoms.

The main hypotheses it aims to test are:

1. As shown in mice, a diversity of optimistic and pessimistic dopamine reward signals exists in the human ventral tegmental area (VTA) and the ventro-rostral basal ganglia circuit. 2. Pessimistic neurons are more severely affected by neurodegeneration in PD.

Researchers will compare the diversity of optimistic and pessimistic dopamine reward signals in patients with PD and healthy participants to see if there is a skewed distribution of optimistic and pessimistic reward signals in PD. Participants will play a task probing reward- and movement related brain activity in an MRI scanner. Researchers will derive functional topographic maps of optimism/pessimism in VTA, substantia nigra pars compacta (SNc), striatum and cortical areas such as the anterior cingulate cortex (ACC).

In sub-study 1, participants will be tested on one study day where patients with PD are tested in the off-medication state (40 control participants, 40 patients with PD).

In sub-study 2, to test whether/how dopaminergic medication affects the distribution of optimism/pessimism, participants will be tested on two study days (30 control participants, 30 patients with PD). Patients with PD are tested one day in the off-medication state, another day in the on-medication state (order counterbalanced between patients with PD). Control participants are tested on two days without medication challenge to test for test-retest effects.

Eligibility criteria

Qualifiers

At least 35 years of age.

Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease

Akinetic-rigid type PD

Stable antiparkinsonian medicine for 4 weeks without major side effects such as dyskinesia or on-off periods.

Disqualifiers

Female participants of childbearing age must not be pregnant, and they must use contraception.

Breastfeeding.

History of other neurologic or psychiatric disease other than depression.

Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

140 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Danish Research Centre for Magnetic Resonance

Lead sponsor

University Hospital Bispebjerg and Frederiksberg

Collaborator